{"id":17916,"date":"2026-03-06T11:04:00","date_gmt":"2026-03-06T11:04:00","guid":{"rendered":"https:\/\/www.colorectalcancercanada.com\/?post_type=drug&#038;p=17916"},"modified":"2026-03-26T15:51:46","modified_gmt":"2026-03-26T15:51:46","slug":"pembrolizumab","status":"publish","type":"drug","link":"https:\/\/www.colorectalcancercanada.com\/fr\/drug\/pembrolizumab\/","title":{"rendered":"Pembrolizumab"},"content":{"rendered":"<p><strong>Indication<\/strong><\/p>\n<p>Traitement de premi\u00e8re intention chez les patients adultes atteints d&rsquo;un cancer colorectal (mCRC) non r\u00e9s\u00e9cable ou m\u00e9tastatique pr\u00e9sentant une instabilit\u00e9 microsatellitaire \u00e9lev\u00e9e (MSI-H) ou un d\u00e9ficit de r\u00e9paration des m\u00e9sappariements (dMMR).<\/p>\n","protected":false},"template":"","crc_subtype":[434],"drug_stage":[402],"therapy_line":[418],"health_canada_approval":[404],"cda_review":[405],"cda_recommendation":[406],"inesss_review":[407],"inesss_recommendation":[408],"pcpa_status":[409],"public_reimbursement":[411,410,454,450,451,414,453,413,412,452],"class_list":["post-17916","drug","type-drug","status-publish","hentry","crc_subtype-ims-e-msi-h-instabilite-microsatellitaire-elevee","drug_stage-iv-fr","therapy_line-premiere-ligne","health_canada_approval-approved-fr","cda_review-completed-fr","cda_recommendation-positive-fr","inesss_review-termine-fr","inesss_recommendation-positive-fr","pcpa_status-completed-fr","public_reimbursement-alberta-fr","public_reimbursement-colombie-britannique-fr","public_reimbursement-i-p-e","public_reimbursement-manitoba-fr","public_reimbursement-n-b","public_reimbursement-ns-fr","public_reimbursement-on","public_reimbursement-qc-fr","public_reimbursement-sk-fr","public_reimbursement-t-n-l"],"_links":{"self":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug\/17916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug"}],"about":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/types\/drug"}],"wp:attachment":[{"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/media?parent=17916"}],"wp:term":[{"taxonomy":"crc_subtype","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/crc_subtype?post=17916"},{"taxonomy":"drug_stage","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/drug_stage?post=17916"},{"taxonomy":"therapy_line","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/therapy_line?post=17916"},{"taxonomy":"health_canada_approval","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/health_canada_approval?post=17916"},{"taxonomy":"cda_review","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/cda_review?post=17916"},{"taxonomy":"cda_recommendation","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/cda_recommendation?post=17916"},{"taxonomy":"inesss_review","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/inesss_review?post=17916"},{"taxonomy":"inesss_recommendation","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/inesss_recommendation?post=17916"},{"taxonomy":"pcpa_status","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/pcpa_status?post=17916"},{"taxonomy":"public_reimbursement","embeddable":true,"href":"https:\/\/www.colorectalcancercanada.com\/fr\/wp-json\/wp\/v2\/public_reimbursement?post=17916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}